Number Needed to Treat with Biologics in Type-2 Inflammation COPD: A Systematic Review and Meta-Analysis.

COPDJul 6, 2026 (epub)
Clinical ResearchPulmonology

Qinqin Wang, Qianli Ma

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the number needed to treat (NNT) for type-2-targeted biologics in adults with moderate-to-severe COPD. The analysis found that patient-based NNTs for reducing exacerbations were 12-17 for dupilumab and 11-16 for mepolizumab, while event-based NNTs were 3 for dupilumab and 5 for mepolizumab, indicating significant therapeutic benefits.

Key findings

  • Patient-based NNT for dupilumab was 12-17 and for mepolizumab was 11-16 for reducing exacerbations.
  • Event-based NNTs were 3 for dupilumab and 5 for mepolizumab at a baseline exacerbation rate of 1.055 per year.
  • Dupilumab showed improvements in pre-bronchodilator FEV1, SGRQ, and E-RS-COPD.
  • Mepolizumab did not consistently show improvements across non-exacerbation outcomes.

Why it matters

Understanding the NNT for biologics in COPD can help clinicians assess the therapeutic value of these treatments in managing exacerbations and improving patient outcomes, guiding treatment decisions.

Source

PubMed · PMID 42405817

Published in COPD. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pulmonology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.